Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. (Q46727005)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18308793%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

title

Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18308793%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

0 references

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18308793%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Iluminada Corripio

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18308793%20AND%20SRC:MED&resulttype=core&format=json

Carles Garcia-Ribera Comdor

3 January 2020

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18308793%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

author name string

A M Catafau

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18308793%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

M M Penengo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18308793%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

G Nucci

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18308793%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

S Bullich

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18308793%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

R Gomeni

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18308793%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

E Merlo-Pich

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18308793%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Barcelona Clinical Imaging in Psychiatry Group

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18308793%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

language of work or name

English

0 references

publication date

28 February 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18308793%20AND%20SRC:MED&resulttype=core&format=json

Journal of Psychopharmacology

3 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18308793%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18308793%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18308793%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

page(s)

882-894

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18308793%20AND%20SRC:MED&resulttype=core&format=json

Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.

3 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Pharmacokinetics of clozapine and risperidone: a review of recent literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Olanzapine. Pharmacokinetic and pharmacodynamic profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Test-retest variability and reliability of 123I-IBZM SPECT measurement of striatal dopamine D2 receptor availability in healthy volunteers and influence of iterative reconstruction algorithms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Quetiapine. A review of its use in the management of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Risperidone dose and blood level variability: accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Use of liquid chromatography-tandem mass spectrometry for the quantitative and qualitative analysis of an antipsychotic agent and its metabolites in human plasma and urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Clinical pharmacokinetics of quetiapine: an atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Population pharmacokinetics I: background, concepts, and models

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Investigation of target plasma concentration-effect relationships for olanzapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

D2 receptor occupancy under recommended and high doses of olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Therapeutic monitoring of new antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Individual variation in D2 dopamine receptor occupancy in clozapine-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Decrease in human striatal dopamine D2 receptor density with age: a PET study with [11C]raclopride

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Antipsychotic drug doses and neuroleptic/dopamine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

An update of fast-off dopamine D2 atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Significant dissociation of brain and plasma kinetics with antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

Theoretical insights into the mechanism of action of atypical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810

In vivo 123 I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107083810